The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
The Federal Trade Commission on March 6 sued to block GTCR’ s acquisition of Surmodics, alleging that “the deal, which seeks to combine the two largest manufacturers of critical medical device ...
This week's Deal Dispatch has updates on Raizen, Walgreens, TikTok and Canoo. Plus: the FTC is blocking mergers like it's ...
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq ...
The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate ...
The FTC said the deal would give the combined company more than 50per cent of the market for suppliers of hydrophilic ...
The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback